All Blogs / Industries / Medical / Pharmaceutical / Popular

Actavis Must Keep its Older Alzheimer’s Pill on the Market

A federal appeals court ruled that Actavis cannot pull an older Alzheimer’s drug from the market in order to switch patients to a newer, more expensive version before generic competition emerged.

EMA Upholds Recommendation to Suspend Drugs Over ‘Flawed’ Studies

The European Medicines Agency is sticking with a decision to recommend suspending the sale of hundreds of drugs that were authorized for use based on what it called “flawed” studies that were conducted by GVK Biosciences, a clinical research organization based in Hyderabad, India.

A New Amination Reaction

Phil Baran and group have another big new synthetic methods paper out in Science, and it's well worth a look. It's a radical mechanism, based on some earlier work from the group, as you might guess from the conditions: Fe(acac) 2 and triethylsilane in ethanol. Show More Summary

Pharmalot.. Pharmalittle.. As the Weekend Nears: We’re Catching up on Amgen, Merck and Lots More!!

And so, another working week is about to draw to a close. Although we sense things are already slowing down since we have a long holiday weekend coming up on this side of the pond. In any event, this is our treasured signal to daydream about weekend plans and our agenda is rather modest. Show More Summary

A Few Thoughts on the CVS Health-Omnicare Deal

Well, the Bloomberg story from yesterday’s news roundup turned out to be true: CVS Health is acquiring Omnicare. Read the press release. This a great deal for CVS Health, which extends its leadership in specialty dispensing, expands into long-term care and assisted living, and enlarges its generic and brand buying power. Show More Summary

Nepal after the recent earthquakes: reconstruction and vaccine-preventable enteric diseases

In the wake of the recent devastating earthquakes, PLOS Medicine Consulting Editor Lorenz von Seidlein visited Nepal to assess outbreak risks. Lorenz travelled with Anuj Bhattachan, International Vaccine Institute, Seoul, Korea and guidance from Deepak C. Show More Summary

Malaria and Epstein-Barr Virus: A Lethal Combination

A recent study in PLOS Pathogens investigates how Epstein-Barr virus and malaria co-infection may create a lethal combination if the timing is right. Epstein-Barr virus and malaria are two infections that can each be controlled on their...Show More Summary

From Pharma to Farmer: FDA Wants Sales Data on Antibiotics for Livestock

The FDA has proposed a rule that would require drug makers to report the amount of antibiotics that are sold for use in different types of food-producing livestock.

Bristol-Myers Faces a Compulsory License for an AIDS Drug in Peru

The heated battle between drug makers and patient advocates over patents and access to medicines is moving to Peru, where several consumer groups are urging the government to issue a compulsory license for an HIV medicine sold by Bristol-Myers Squibb.

Guess What: Your Peers Are Already Reviewing You

Looks like there are biologists who are getting a chance to figure out what social media can do to communication in their field. Nature News reports on the response to a PNAS paper published late last year from the Mouse ENCODE consortium. Show More Summary

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on CVS, Antibiotics and More!!

Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say 'Every brand new day should...Show More Summary

Crappy Antibodies: Available Now, and for the Foreseeable Future

I made a brief mention of this article yesterday, but I wanted to highlight it. It's a look, from Nature New, at the broader implications of the antibody problem in research. Antibodies are, of course, universal reagents in molecular biology assays. Show More Summary

News Roundup, May 2015: Walgreens, Catamaran, OptumRx, CVS Health, Omnicare, and More

Time to get your barbecue ready for Memorial Day! Before you fire up the grill, dig into this month’s menu of noteworthy news patties, seasoned perfectly for your reading pleasure. In this issue: Get up and close and personal with Alex...Show More Summary

Will the J&J Deal With Achillion Transform the Hep C Market?

Wall Street analysts say the Johnson & Johnson deal with Achillion Pharmaceuticals could eventually chip away at Gilead Sciences revenue and poses a threat to AbbVie.

Hospitals Urge Congress not to Change a Drug Discount Program

Executives from more than 500 hospitals are urging Congressional leaders not to make changes to a prescription drug program that serves indigent patients and bolsters their own bottom lines.

Controlling Proteins, One by One

Here's what looks like a very useful method for turning protein function on and off, reported in a new paper in Nature Chemistry. (This PDF link may work for you). The authors, from the MRC Molecular Biology labs at Cambridge (rightShow More Summary

High Price for Gilead Sciences Hep C Drug Prompts Patent Challenges

Several advocacy groups have filed patent challenges to the blockbuster Sovaldi hepatitis c drug in a bid to widen access to patients in some of the world’s largest countries.

Tom Stossel Attempts to Debunk the Conflict-of-Interest "Myth"

Yesterday, I interviewed Thomas P. Stossel, M.D., visiting scholar at the American Enterprise Institute for Public Policy Research, about his new book, PharmaPhobia, and his call to action against the "Conflict of Interest Movement," which he claims undermines American medical innovation. Show More Summary

Copyright © 2015 Regator, LLC